Clinical Trial

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

Study acronym: STAC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 24, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-13; most recent amendment 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2025-08-18
Trial Details
NCT Number NCT06691243
Lead Sponsor University of Maryland, Baltimore
Collaborators: National Institutes of Health (NIH)
Conditions Cocaine Use Disorder, HIV
Enrollment 40 participants
Start Date 2025-08-07
Primary Completion 2026-07 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-08-24